Blog Article

ICH Q9(R1): What Changed for Quality Risk Management, and What to Do About It

ICH Q9(R1) named subjectivity, made formality a spectrum and pulled supply risk into scope. A head of quality's guide to what changed and what to demand.

A five-by-five risk matrix in navy line art with the whole middle band filled in, and one amber cell in that band marking the hazard that should have scored high. Punch line: Everyone scored it medium. Nobody decided anything.

Open your risk register and count how many live assessments sit in the middle band. If it is most of them, you already know what this post is about.

Across the implementations I have watched, that is the most common pattern, and it is almost never a tooling problem. The matrix is fine. The people filling it in are cautious, busy, and scoring against each other rather than against the hazard. The 2023 revision of ICH Q9 is the first time the guideline names that behaviour as something a head of quality is responsible for managing.

Four additions and two dates

ICH adopted Q9(R1) at Step 4 on 18 January 2023. FDA published it as a final guidance for industry in May 2023, and in the EU it took effect on 26 July 2023.

The process itself did not move. Assessment, control, communication and review are the same four boxes they were in 2005. What the revision added sits around that process:

  • Formality gets its own section, described as a spectrum rather than a formal-or-informal choice.
  • Risk-based decision-making becomes a discipline in its own right, with three routes depending on how structured the decision needs to be.
  • Subjectivity gets a section on managing and minimising it, and the responsibility for doing so is placed with decision makers.
  • Product availability is pulled into scope: quality and manufacturing problems that threaten supply are now something the risk programme is expected to anticipate.

For scale, the 2005 text mentioned formality only in passing, in a few principle sentences, and never used the word subjectivity. The guideline also says it creates no new expectations beyond current regulation. Take that as a description of the law, not of your next inspection.

One scope note. Q9 is a pharmaceutical guideline. If you make devices, your risk standard is ISO 14971 and the vocabulary differs; the management problem below is the same.

A matrix where everything scores medium is a people problem

Here is the sentence from the revision I would put in front of every assessor: subjectivity can impact every stage of a quality risk management process, especially hazard identification and the estimation of probability and severity.

The guideline then names where it comes from. Differences in how people perceive the hazard, which is bias. Risk questions that were never properly defined, so everyone answers a slightly different question. And scoring scales that were poorly designed to begin with, so "likely" means once a month to one person and once a decade to another.

Notice what is not on that list: the software. The revision says subjectivity cannot be completely eliminated, but it may be controlled, and the controls it names are addressing bias and assumptions, using the tools properly, and using the best data you have.

So when a register fills up with medium, ask what is producing that. In my experience it is one of three things:

  • Scoring by consensus in the room. Nobody wants to say "high" and create work, and nobody wants to say "low" and own it if it goes wrong. Medium is where the room settles.
  • A scale nobody calibrated. Severity descriptors like "major" or "moderate" with no anchor in your own history, so each assessor supplies their own.
  • A risk question that was never written down. "Assess the risk of this change" is not a question. "What could this change do to the release test for product X in the next twelve months?" is.

None of those is fixed by a new matrix. All of them are fixed by someone owning the calibration.

What a buried high-risk item costs you

A high-risk item scored medium does not disappear. It sits in the same queue as forty genuinely medium items, with the same review cadence and mitigation budget. Three things then happen.

First, the mitigation is under-sized. A medium score buys a procedural control and a training assignment. A high score would have bought a design change, a second detection point, or a supplier conversation. The difference is real money, spent in the wrong place.

Second, the review never comes. Q9 asks you to review risk when new information arrives; in practice, medium items are reviewed when the annual cycle says so. The deviation that should have re-opened the assessment is handled as a deviation.

Third, when it does fail, the record says you knew. An inspector finds the hazard, the medium score, no rationale, and the deviation eighteen months later. The conversation stops being about the event and becomes about why your programme did not see it.

I do not have an industry number for that. In every case I have seen, calibrating the scale beforehand would have cost a fraction of the investigation afterwards.

Formality is a dial, not a switch

This is the change most heads of quality should be pleased about, and the one I see least used.

The revision says formality is a continuum, and where you sit on it should reflect uncertainty, importance and complexity. High on any of those, turn the dial up: cross-functional team, a formal tool, a stand-alone report. Low on all three, turn it down: handle the risk inside the existing procedure, no separate report, no team.

You can stop over-documenting. Most registers are full of low-uncertainty, low-importance calls that a rule in a procedure could have made. The guideline now explicitly allows rule-based decisions with no new assessment where a policy or limit already exists because the risk was understood earlier.

You can no longer under-document the critical. The same section says resource constraints should not be used to justify a lower level of formality. "We did not have time for a cross-functional review" is now a sentence the guideline anticipates and rejects.

The management decision is to write down, in your quality system, how the dial gets set. The guideline asks for exactly that. Most programmes never have, so every assessor decides alone.

The decision is now its own deliverable

The 2005 text treated the decision as what happened after the matrix was filled in. The revision gives it a section, and the effect on your records is direct.

In the guideline's framing, decision-making starts before the assessment, with how much effort and documentation to apply, and runs through which hazards exist, which controls are needed, whether the residual risk is acceptable, and how the outcome is communicated and reviewed. Every one of those is a decision with a maker, a basis and a date.

So a completed matrix is not a completed assessment. A grid of numbers with an approver's name tells a reviewer what you scored, not why the residual risk was acceptable, what the probability estimate rested on, or who had the authority to accept it.

A score slip with severity, probability and a medium score filled, and the rationale emptyOne horizontal slip. Three cells hold 5, 2 and M. The rationale well is an empty amber box.52MSeverityProbabilityScoreRationale

The revision adds one more line quality teams will recognise: it is important to ensure the integrity of the data behind a risk decision.

Could the last ten risk decisions your programme made be reconstructed from the record alone? If the answer depends on finding the person who was in the meeting, the decision is not yet a deliverable.

Supply and shortage risk are now quality's business too

This is the section most quality teams skim, and I think it will change the shape of the job.

The revision says plainly that quality and manufacturing problems, including GMP non-compliance, are a significant cause of shortages, and that patients are served by risk-based prevention. It names three factors that affect supply reliability: process variability and the state of control, the condition of facilities and equipment, and oversight of outsourced activities and suppliers.

Two things follow for a head of quality. Supplier performance and process capability are now quality risks, not only operations metrics.

For most sites that means the supplier scorecard, the process-capability trend and the risk register have to talk to each other. Today they usually belong to three people who meet once a quarter.

Who owns the calibration?

This is the question the whole revision turns on, and it is answered where people do not look: the responsibilities section.

Decision makers, the guideline says, should assure that subjectivity in quality risk management activities is managed and minimised. Not assessors. Not the tool. The people with authority over the programme.

Someone senior owns the scales: they decide what "major" means in your context, checks that similar hazards score similarly across sites, and re-anchors the probability bands when the data says they have drifted. If you cannot name that person, nobody owns it, and the register will keep filling with medium.

The risk assessment matrix entry in our glossary covers what a calibrated scale looks like. Calibration is a standing responsibility with a name against it, not a one-off at implementation.

Running on 2005 habits versus reading R1

Put the two side by side and the gap is behavioural, not procedural.

Programme on 2005 habits Programme that has read R1
Scoring scale Descriptors from the template, never anchored Anchored to the firm's own data; a named owner re-calibrates
A register full of medium Accepted as how people score Treated as a subjectivity signal and investigated
Level of effort The same for every assessment Set by uncertainty, importance, complexity; written down
The record The score and an approver The score, the reasoning, the evidence, the residual-risk decision
Supplier and process risk Operations metrics Quality risks with a place in the register
Review On the annual cycle When new information arrives, including a deviation

None of the right-hand column requires a new process. All of it requires a management decision about what the programme is for.

What to demand of your own programme first, then of a vendor

Start at home, because a vendor cannot fix a scale you have not calibrated.

Of your own programme, demand four things: a written approach to formality, so the dial is set by a rule rather than by whoever is busiest; a named owner for the scales, with a review cadence; rationale on every score above the lowest band; and a defined route for a deviation or change to re-open the assessment it relates to.

Of a vendor, ask about visibility, not intelligence. Nothing in Q9(R1) asks software to make the judgement, and I would be wary of anyone who says theirs does. What you want is for your people's judgement to stay visible and reviewable:

  • Can we define our own severity, probability and detectability bands, and change them under control when the data says so?
  • Does each score carry the reasoning behind it, or only the number?
  • Can a reviewer see the deviation, change or CAPA that raised the assessment without leaving the record?
  • When the risk is accepted, does the record show who accepted it and on what basis?
  • Can two assessments of the same hazard be put side by side, so calibration drift is something we can see?

If the answers are yes, the tool will show you your programme honestly, and a register that still fills with medium becomes information you can act on.

Where Complere fits when the judgement has to stay visible

The scale is yours. You set the severity, probability and detectability bands and the thresholds between them, so a score means what your programme decided it means, not what a template shipped with.

The reasoning stays next to the score. Each assessment can carry the rationale behind the numbers, so a reviewer reads why the residual risk was acceptable instead of reconstructing it.

The record that raised the risk stays attached. An assessment stays linked to the deviation, change or CAPA it came from, so the new information that should re-open it is in the same place, not in another system.

The decision has a name and a date. Who accepted the risk, when, and at what level is part of the record, which is what the revision's decision-making section asks you to be able to show.

Your people make the risk call, and the calibration behind it is management's job. What the software owes you is to keep that call, and the reasoning under it, where the next reviewer can find it.

Frequently asked questions

Questions readers commonly ask about ICH Q9(R1): What Changed for Quality Risk Management, and What to Do About It.

When did ICH Q9(R1) take effect?

ICH adopted Q9(R1) at Step 4 on 18 January 2023, with a minor typographical correction on 26 January 2023. FDA published it as a final guidance for industry in May 2023 (CDER and CBER). In the EU it took effect on 26 July 2023 through EMA's Step 5 adoption. If your risk management procedure still cites the 2005 text without change, it is more than two years behind the version regulators are reading.

Does Q9(R1) create new requirements?

The guideline says it is not intended to create new expectations beyond current regulatory requirements. Read that as a statement about the law, not about your inspection. The revision adds sections on formality, risk-based decision-making, subjectivity and product availability, and inspectors read those sections. A programme that has never addressed assessor bias will find the conversation different from the one it had in 2019.

What is the single most useful change for a head of quality?

The formality spectrum. It gives you permission to run low-stakes decisions through lightweight, rule-based routes and spend your cross-functional time on the assessments where uncertainty and importance are high. Most programmes are spending the same effort on every assessment, which means they are over-documenting the trivial and under-thinking the critical at the same time.

Disclaimer: This article discusses the ICH Q9(R1) Quality Risk Management guideline (Step 4, 18 January 2023), FDA’s May 2023 guidance adopting it, and EMA’s Step 5 adoption effective 26 July 2023. ICH Q9 is a pharmaceutical guideline; medical device manufacturers work to ISO 14971. It is general educational content, not legal or regulatory advice, and does not replace your own procedures or SME review.

About the author

Founder, Complere

Compliance and quality-systems specialist writing for regulated SaaS buyers in pharma, medical device, biotech, and CDMO. All posts reviewed against current FDA, MHRA, EMA, ICH, and PIC/S guidance before publication.

Continue Exploring

Explore related topics, modules, and compliance resources for a deeper understanding of your quality system.

483 response companion post
Related

FDA Is Rewriting How You Respond to a 483. Are Your CAPAs Ready?

What a post-QMSR 483 response has to produce in 15 business days, including the risk basis behind each preventive action.

Explore
Slow CAPAs companion post
Related

If Your CAPAs Are Slow, Your QMS Architecture Is Wrong (Not Your Team)

Where the wasted days in a CAPA cycle sit, and why the fix is structural rather than a staffing problem.

Explore

Related from the blog

More from the Complere editorial team on quality, validation, and inspection readiness.

Investigation & Risk

OOS Investigation — What FDA Still Expects in 2026

Barr still rules retesting. FDA's OOS guidance got a Level 2 revision in 2022, not a rewrite. Phase I/II files, averaging, and CAPA linkage under inspection.

Read the article
Investigation & Risk

Deviation, CAPA, and Change Control in Pharma: Why They Must Stay Linked

§211.192 asks for conclusions and follow-up, not a closed form. The five seams where the deviation→CAPA→change chain breaks, and what an investigator traces.

Read the article
Regulatory & Inspection

QMSR Transition Gap Assessment: How to Run One

How a device site scopes, runs, records and signs a QMSR gap assessment against ISO 13485:2016 as incorporated, and how the gaps flow into change control.

Read the article

See a risk assessment that keeps the reasoning

Walk through how a severity, probability and detectability score stays attached to the rationale behind it, the record that raised it, and the decision it led to.